資料下載
Data download
熱門搜索：
Fitzgerald Industries International代理
Envirologix 轉基因快速檢測試紙
Epitomics現貨抗體目錄
ABgene代理30
EVE™ Slide（EVE細胞計數板）
Cayman Chemical 特約代理
法國ID-VET
Sinobio公司產品介紹
美國Sutter 玻璃毛坯 BF100-50-10
genview
D12079BWestern Diet(高純度飼料)
polysciences公司中國總代理
TEAA Solution（貨號：553303;SP5890）
LSPN-50ABMI公司LYSOSTAPHIN中國總代理
Abcam代理
天然小鼠補體C1q蛋白
發布時間：2024/3/4
點擊次數：430
matriksbiotek2024年價格表
Matriks Biotek專門生產針對抗體藥的ELISA試劑盒，用于檢測抗體藥的體內含量或因用于產生的針對相應抗體藥的抗體的體內含量。Matriks Biotek®, SHIKARI®和KLONART®為Matriks生物技術公司注冊的產品商標。其產品達到ISO 13485 & CE IVD標準。
MatriksBiote抗體藥是一類相對新型的生物制劑。檢測抗體藥及其抗體水平在治療和個性化用藥上具有重要意義。大量的臨床和制藥公司都在致力于抗體藥物的濃度水平和療效的研究。
特別告知：為保證產品質量與良好性能，所以在購買相應產品的同時我司會收取一定量的運輸費用！！！本次報價有效時間為2024年1月8日---2024年12月14日。
| 貨號 | 品名 | 規格 | 價格 | 品牌 | 貨期 | 價格來源 |
| ABA-FD-ORE | Abatacept (Orencia®) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| ABA-QLS-ORE | Abatacept (Orencia®) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| ABA-QNS-ORE | Abatacept (Orencia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| ADA-FD-HUM | Adalimumab (Humira®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| ADA-QLS-HUM | Adalimumab (Humira®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| ADA-QNFT-HUM | Adalimumab (Humira®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| ADA-QNS-HUM | Adalimumab (Humira®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| ADA-SPEC-ADA | Adalimumab (Humira®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| AFL-FD-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| AFL-FD-SENS-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| AFL-QLS-EYL | Aflibercept (Eylea®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| AFL-QNS-EYL | Aflibercept (Eylea®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| ATE-FD-TEC | Atezolizumab (Tecentriq®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| ATE-QLS-TEC | Atezolizumab (Tecentriq®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| BEV-FD-AA | Bevacizumab (Avastin®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| CAN-FD-ILA | Canakinumab (Ilaris®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| CAN-QLS-ILA | Canakinumab (Ilaris®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| CAN-QNS-ILA | Canakinumab (Ilaris®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| DAR-FD-DAR | Daratumumab (Darzalex®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| DAR-QLS-DAR | Daratumumab (Darzalex®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| DEN-QNS-PRO | Denosumab (Prolia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| DUR-FD-IMF | Durvalumab (Imfinzi®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| DUR-QLS-IMF | Durvalumab (Imfinzi®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| ETA-FD-ENB | Etanercept (Enbrel®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| EVO-FD-REP | Evolocumab (Repatha® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| EVO-QLS-REP | Evolocumab (Repatha® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| INF-FD-REMI | Infliximab (Remicade®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| INF-FD-REMS | Infliximab (Remsima®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| INF-QLS-REMI | Infliximab (Remicade®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| INF-QLS-REMS | Infliximab (Remsima®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| INF-QNFT-REMI | Infliximab (Remicade®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| INF-QNFT-REMS | Infliximab (Remsima®) Antibody screening - Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| INF-QNS-REMI | Infliximab (Remicade®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| INF-QNS-REMS | Infliximab (Remsima®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| INF-SPEC-INF | Infliximab (Remicade®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| NIV-FD-OPD | Nivolumab (Opdivo®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| PAL-FD-SYN | Palivizumab (Synagis® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| PAL-QLS-SYN | Palivizumab (Synagis® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| PAL-QNS-SYN | Palivizumab (Synagis® ) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發 |
| PEM-FD-KEY | Pembrolizumab (Keytruda®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| RAN-FD-LUC | Ranibizumab (Lucentis®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| RIT-FD-RM | Rituximab (Rituxan®, Mabthera®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| RIT-QLS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| RIT-QNS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| SEC-FD-VER | Secukinumab (Cosentyx® , Verxant®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| SEC-QLS-VER | Secukinumab (Cosentyx® , Verxant®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| TOC-QNS-ACT | Tocilizumab (Actemra®) Antibody screening - Quantitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| TRA-FD-HH | Trastuzumab (Herceptin®, Herclon®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發 |
| UST-QLS-STE | Ustekinumab (Stelara®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| VED-FD-ENT | Vedolizumab (Entyvio®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
| VED-QLS-ENT | Vedolizumab (Entyvio®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發 |
（*此為部分產品價格完整價格請下載文件）
關鍵詞：matriksbiotek、Matriks Biotek®、KLONART®、SHIKARI®、ELISA試劑盒
文件下載
當前位置：
